Sanofi exercises option to license NK cell engager program from Innate Pharma

Innate Pharma (IPHA) and Sanofi (SNY) announced that Sanofi has exercised its option to license a natural killer, or NK, cell engager program in solid tumors from Innate’s Anket platform pursuant to the terms of the research collaboration and license agreement signed in December 2022. Following a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization. Sanofi still retains the option to one additional Anket target as per the license agreement. Under the terms of the December 2022 agreement, Innate will receive a EUR 15M payment for the exercise of this option. Innate Pharma is eligible for up to EUR 1.35B total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.